A potential vaccine against the novel coronavirus causing the covid-19 outbreak has been created in a University of Pittsburgh lab.
Researchers say the first phase of human clinical trials — which would include healthy volunteers in the Pittsburgh area — could start in the coming months.
Scientists at the University of Pittsburgh School of Medicine announced Thursday that the vaccine, when tested in mice, produces antibodies specific to the coronavirus SARS-CoV-2 that could be enough to fight off the virus. Testing the vaccine in mice doesn’t guarantee efficacy in humans.
“We’re ready to initiate clinical trials as soon as we are able to meet the necessary requirements,”
Dr. Louis Falo, professor and chair of dermatology at Pitt’s School of Medicine and
UPMC, said during a press briefing.
In making the announcement, Falo invoked Pitt’s own Jonas Salk — the medical pioneer whose team developed the world’s first effective polio vaccine in 1955.
The vaccine findings are part of the first peer-reviewed study describing a potential vaccine, according to the Pitt researchers. The paper appeared in
EBioMedicine on Thursday, which is published by
The Lancet, one of the oldest peer-reviewed medical journals.
While human testing typically requires at least a year, Falo said Pitt is working with federal agencies to speed the process.
“This particular situation is different from anything we’ve ever seen, so we don’t know how long the clinical development process will take. Recently announced revisions to the normal processes suggest we may be able to advance this faster,” said Falo, who is senior co-author of the research.
The researchers are applying for approval from the U.S. Food and Drug Administration.